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Ans H Tiessen1*, Karin M Vermeulen2, Jan Broer3, Andries J Smit4 and Klaas van der Meer1Abstract
Background: Cardiovascular disease (CVD) is largely preventable and prevention expenditures are relatively low.
The randomised controlled SPRING-trial (SPRING-RCT) shows that cardiovascular risk management by practice
nurses in general practice with and without self-monitoring both decreases cardiovascular risk, with no additional
effect of self-monitoring. For considering future approaches of cardiovascular risk reduction, cost effectiveness
analyses of regular care and additional self-monitoring are performed from a societal perspective on data from the
SPRING-RCT.
Methods: Direct medical and productivity costs are analysed alongside the SPRING-RCT, studying 179 participants
(men aged 50–75 years, women aged 55–75 years), with an elevated cardiovascular risk, in 20 general practices in the
Netherlands. Standard cardiovascular treatment according to Dutch guidelines is compared with additional counselling
based on self-monitoring at home (pedometer, weighing scale and/ or blood pressure device) both by trained practice
nurses. Cost-effectiveness is evaluated for both treatment groups and patient categories (age, sex, education).
Results: Costs are €98 and €187 per percentage decrease in 10-year cardiovascular mortality estimation, for the control
and intervention group respectively. In both groups lost productivity causes the majority of the costs. The incremental
cost-effectiveness ratio is approximately €1100 (95% CI: -5157 to 6150). Self-monitoring may be cost effective for
females and higher educated participants, however confidence intervals are wide.
Conclusions: In this study population, regular treatment is more cost effective than counselling based on
self-monitoring, with the majority of costs caused by lost productivity.
Trial registration: Trialregister.nl identifier: NTR2188
Keywords: Cost-effectiveness, Arteriosclerosis, Cardiovascular diseases, Primary health care, Prevention and control,
Self-managementBackground
Cardiovascular diseases (CVDs) are a leading cause of
death both worldwide (29% of all deaths, 2004) [1] as in
the Netherlands (28% of all deaths, 2011; Statistics
Netherlands). CVDs are to a large extent preventable
[2]. In 2009, in Dutch family practice, €39 million was
spent on non-pharmaceutical cardiovascular preventive
activities, i.e. risk profiling, blood pressure (BP)
measurements and lifestyle counselling [3]. Annual costs
at patient level were estimated for the Dutch situation, in-
cluding doctor’s visits, repeat prescriptions, drug costs and* Correspondence: a.h.tiessen@umcg.nl
1University Medical Center Groningen, Department General Practice,
University of Groningen, Groningen, The Netherlands
Full list of author information is available at the end of the article
© 2013 Tiessen et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orexcluding diagnostics and productivity costs, as €293 for
statin use and €258 for antihypertensives [4].
Lifestyle interventions appear to be cost effective in
reducing cardiovascular risk [5]. A Dutch study found
that preventive cardiac medication, following a 2006
revised guideline, was also cost effective [4]. This guide-
line recommended a broader indication for starting
medication than previous guidelines and was also the
basis for SPRING study (Self-monitoring and Prevention
of RIsk factors by Nurse practitioners in the region of
Groningen), of which the cost effectiveness is discussed
in this paper. Drug treatment of hypertension and dy-
slipidaemia for cardiovascular prevention according to
Canadian guidelines appeared to be cost effective as well
[6]. However, Grover et al. concluded that treatment isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cluded that -although effects are more pronounced in
older age groups- health gain per prevented case is
larger for all age groups up to the age of 70 [4]. Several
studies on cost-effectiveness of combined screening, life-
style and pharmaceutical interventions in (cooperation
with) primary care indicated increased life expectancy
without increased costs [7-10], were inconclusive in one
study, [11] or were depending on differences in
assumptions on long-term duration of effect [12-14]. Most
of the previously mentioned studies did not use a societal
perspective (i.e. taking into account absence at work and
transportation of participants), except Rasmussen and
Salkeld [7-14]. Rasmussen and Salkeld took into account
prevented productivity losses for working individuals ex-
periencing a cardiovascular event, but did not take into ac-
count productivity losses due to the intervention [7,11]. So,
there is a need for cost effectiveness-analysis of cardiovas-
cular preventive interventions in general practice from a so-
cietal point of view.
For the SPRING-RCT we reported that combined life-
style and drug intervention by practice nurses in persons
with a mild to moderate cardiovascular risk resulted in a
small but significant decrease of cardiovascular risk after
one year (ΔSCORE 10 year risk of cardiovascular mortal-
ity –1.71% (SD 2.95) for both groups together), [15]
without significant additional effect of intensive treatment
with self-monitoring compared with standard treatment
[16]. Interventions that cause modest risk reduction in
individuals, like the SPRING trial, may have a substantial
cumulative effect when applied on the population as a
whole (prevention paradox). Before implementation of
such an intervention program, costs and cost-effectiveness
should be considered.
The objectives of this paper are to assess the costs and
cost-effectiveness of cardiovascular prevention by practice
nurses from a societal perspective in both treatment
groups of the SPRING-RCT, and specify the costs of
components of the intervention and the cost-effectiveness
for subgroups (age, sex, level of education).
Method
SPRING population and intervention
The economic evaluation was conducted using data
gathered in the SPRING-RCT. Between June 2008 and
August 2009 randomly selected individuals from 20 gen-
eral practices (GPs) were invited for a screening. Men
aged 50–75 years and women aged 55–75 years, with an
estimated SCORE 10-year cardiovascular risk of cardio-
vascular mortality ≥5% [15], at least one treatable risk
factor (smoking, hypertension, lack of physical activity
or overweight) and without history of CVD, diabetes
mellitus, thyroid dysfunction or an estimated life expect-
ancy <2 years, were randomised at patient level into twogroups. The control group received standard treatment
according the 2006 Dutch general practitioner’s guide-
line, [17] conducted by specially trained practice nurses.
The intervention group additionally received counselling
based on self-monitoring at home, with pedometers,
weighing scales and/or BP devices. After one year 179
participants were analysed, the primary outcome was the
SCORE cardiovascular risk estimation. The mean effect
for the control group was 1,63% decrease in SCORE
10-year risk of fatal CVD; the mean decrease for the
intervention group was 1,79%. The SPRING study was
approved by the Medical Ethics Review Committee of
the University Medical Centre Groningen (reference num-
ber 2007/232). For more information on study design and
outcomes, see Tiessen et al [16].
Cost calculation
Total costs were calculated for both treatment groups.
Total costs consisted of direct costs (medication, time
spent by medical staff, self-monitoring equipment,
patient transport to the practice) and productivity losses
(absence at work of the working individuals that parti-
cipated). Costs of intangibles (suffering/adverse effects) and
medical costs not directly related to the study were not
taken into account.
The staff costs of the visits to the practice nurse were
based on the registered total visit time and standard
hourly costs of practice nurses in general practice in the
Netherlands (Table 1). As the practice nurses reported
that time spent on consultation with the general practi-
tioner about participants was negligible, this was not
taken into account. Productivity costs of participants
were calculated for participants that were employed in a
paid job and were based on duration of the visits plus 30
minutes/visit as transportation time, using mean salary
costs stratified by gender [18]. Transportation costs to
the practice for the participants were based on the aver-
age distance for Dutch inhabitants to their GP’s of
1.1 km [18]. Prices of pedometers, weighing scales and
BP devices were based on average customer prices for
these devices and were calculated for participants who
had actually used the self-monitoring devices. Only
medication that was newly added or for which the dos-
age was adapted during the treatment, was taken into
account. 2012 prices of generic medication were used,
including value added tax, and a pharmacists allowance
for every 3 months.
Cost-effectiveness analysis
In order to get an impression of the balance between
additional costs that have to be invested with the new
risk management strategy, and the health gains of this
strategy, a cost effectiveness analysis was performed. The
effectiveness measure was the SCORE cardiovascular
Table 2 Total costs and costs of different aspects of the
treatment for complete cases in both groups per year (€)
Control group Intervention group
(N = 89) (N = 87)
Total cost per individual 160 335
Productivity of participants 72 139
Transport to practice for
participants
9 17
Medical staff 55 110
Self-monitoring equipment 10 44
Medication adjustments 15 25
Statin 3 11
Thiazides 11 10
Beta blocker 0 1





*ACE = angiotensin converting enzyme.




0.85 Vektis, information centre on costs and
quality of health care in the Netherlands,
established by health care insurers.
Mean salary costs
men (€/hour)
32.49 Manual Hakkaart-van Roijen et al. [18]
Mean salary costs
women (€/hour)
25.94 Manual Hakkaart-van Roijen et al. [18]
Transportation costs
per visit
3.44 1.1 km * €0.20/km (back and forth:
€0.44) + €3 parking costs, based on the
manual of Hakkaart-van Roijen et al. [18]
Weighing scale 45 Mean price according to the
“Consumentenbond” (Dutch consumers
organisation)
Pedometer 40 Mean price according to
“thuisvergelijken.nl” (website with
reviews on web shops)
Blood pressure
device




5 Price according to “weightwatchers.nl”
Medication variable 2012 prices according to
“medicijnkosten.nl”, site of the College of
Health Insurances
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cular mortality risk). As the duration of the study was
one year, costs were not discounted (discounting is com-
mon in cost effectiveness studies with a longer duration,
when costs are made at the start and future benefits are
expressed in today’s values). Cost effectiveness ratios
(CERs) in €/% SCORE were calculated for both treat-
ment groups separately. Incremental cost effectiveness
ratios (ICERs) (expressed as difference in costs between
the two methods/ difference in % SCORE) were calculated
to compare the standard treatment and the intervention
treatment from the SPRING-RCT with regard to both
costs and effects. In addition, subgroup analyses were
performed for different patient categories. For both
groups cost and effect pairs were bootstrapped 5000
times from the trial data, which means that based on a
‘random sample with replacement’ from the original
trial data, 5000 new data sets were drawn, that were
used to estimate the ICER 95% confidence interval. In
addition, a cost effectiveness plane was constructed to
graphically display the location of the estimates (right
upper quadrant: more effective and more expensive,
right lower quadrant: more effective and less expensive,
left upper quadrant: less effective and more expensive
and left lower quadrant: less effective and less expen-
sive) [19]. Finally a cost effectiveness-acceptability curve
was computed to estimate the change the new risk
management strategy is cost effective given an rage of
different amounts of money a decision maker might be
willing to pay for one additional unit of health [20].Results
Table 2 shows average costs per participant in both
study groups and the contribution of different treatment
aspects on total costs. Based on the mean effect of 1,63%
and 1,79% decrease in SCORE risk estimation for the con-
trol and intervention group respectively, [16] the CERs are
€98 and €187/% decrease SCORE risk estimation.
The mean difference between both groups regarding
treatment effect is 0.16% (95% CI −1.66 – 1.98) SCORE
risk estimation. The mean difference regarding costs is
€175 (95% CI 80–270). The ICER, therefore, is €1082,
which means that for the intervention group approxi-
mately €1100 has to be invested extra to obtain 1% extra
decrease of SCORE risk estimation. The 95% confidence
interval for the ICER based on 5000 bootstrap repli-
cations is -€5157 to €6150. The replications are depicted
as a cost effectiveness plane (Figure 1a). The location of
the incremental cost effectiveness pairs is above the
horizontal axis, which indicates the higher costs with the
intervention group treatment compared with the control
group treatment. With regard to the effectiveness, there
is considerable uncertainty: 35% of the pairs are left
from the y-axis, indicating more effect for the control
group treatment and 65% are right from the y-axis, indi-
cating more effect of the intervention group treatment.
Figure 1b depicts that irrespective of the amount a deci-
sion maker is willing to pay, the probability of the inter-
vention treatment being more cost effective than the
control treatment is at most 60%.
Table 3 shows CER’s and ICER’s for subgroups. For all
subgroups the cost effectiveness ratio (CER) is lower for
the control treatment compared with the intervention
treatment. The two columns at the right side of the table
Figure 1 Scatter plot of bootstrapped costs and effects (a) and value of ceiling ratio (b) for the whole study population.
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group compared with the control group for the sub-
groups. ICERs for the subgroup pairs show that the
intervention treatment was most cost effective for
females and participants aged >65 years and to a lesser
extent also for higher educated participants. However,
confidence intervals are very large. The results for the
subgroups are also depicted as cost effectiveness planes
and value of ceiling ratios in Figure 2.Discussion
Main findings
In this population, the costs of cardiovascular prevention
were higher in the intervention group, with annual costs
per individual of €160 (control group) compared with
€335 (intervention group). Costs per percent decrease in
estimated 10-year cardiovascular mortality of €98 com-
pared with €187, for the control and intervention group
respectively. An added role for self-monitoring can be
considered only for females and higher educated indivi-
duals. For both groups costs predominantly consisted of
societal costs and staff time and not of medication.Table 3 Effect (Δ% SCORE* risk assessment), cost (€), CER* (€/
subgroups
Control group Intervention
Effect Costs CER Effect C
Sex ♂ 1,7 155 91 1,6 3
♀ 1,5 171 114 2,3 4
Age ≤65y 1,8 184 102 1,8 3
>65y 1,5 133 92 1,8 3
Educ.* low 2,4 174 74 1,8 3
high 1,3 157 121 1,8 3
*SCORE = systematic coronary risk evaluation (estimated 10-year cardiovascular mor
ratio, Educ. = educational level.Explanation and comparison with existing literature
The present study adds valuable new information com-
pared with previous studies, as both costs and effects are
based on an actual practice setting, which makes the
outcomes more generalizable. In addition, societal costs
were included, which is recommended to allow a broad
perspective [21]. Lost productivity due to practice visits
caused the majority of costs and is usually not taken into
account.
The time investment of both medical staff and parti-
cipants not only caused the main cost driver in both
groups, but also the difference between both groups
(Table 1). The number of visits of intervention group
participants was almost twice the number of the control
group participants and also the duration per visit was
slightly longer in the intervention group [16]. All interven-
tion group participants were offered lifestyle counselling
and home collected self-monitoring results were discussed
during the visits. The productivity cost estimates may have
been on the high side with 30 minutes transportation time,
and with some working individuals probably having part-
time jobs with planned visits during spare time. Of minor
influence were the increased costs of self-monitoring% SCORE) and ICER* (Δ €/ Δ% SCORE) in specific
group ICER (95% CI) Effect Costs
osts CER
01 187 −1578 (−39811 – 41036) - +
20 185 325 (−2662 – 2601) ++ +
03 167 5865 (−3257 – 3363) + +
76 213 768 (−4076 – 4759) + +
69 208 −340 (−3649 – 3793) – +
19 182 351 (−3402 – 2923) + +







Figure 2 Scatter plot of bootstrapped costs and effects (a) and value of ceiling ratio (b) for subgroups: I: males, II: females, III: age
≤65y, IV: age >65y, V:low educated individuals, VI: high educated individuals.
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group. Despite self-monitoring not being part of the con-
trol group treatment, some self-monitoring costs were
made due to BP measurements (on participant’s initiative)
at home.
Based on De Bekker-Grob et al. with €39 million
spend on non-pharmaceutical cardiovascular preventive
activities and €181 million on medication, we expected
that costs of modified medication would be relatively
high [3]. In the present study however, these had only
minor influence and consisted in both groups mainly of
statins and thiazides. Medication costs in the SPRING
study may be even overestimated, as we calculated costs
as if all adjusted medication was prescribed for the
whole study period whereas mostly participants were
advised first to adjust their lifestyles. De Bekker-Grob
et al. found a large difference in medication prescription
between different GP’s. We did not study the differences
in prescriptions between practices, but this probably is
of minor influence in this study because medication
adjustments were advised by the study protocol. As
mentioned before, Kok et al. estimated for the Dutch situ-
ation annual costs as €293 for statin use and €258 for
antihypertensives [4]. Compared with the Kok et al. the
costs in the SPRING-RCT appear to be much lower, des-
pite in the SPRING-RCT societal costs were taken into
account. The goal of Kok et al. was not to estimate annual
costs however, it was one step in estimating the cost-
effectiveness of a new guideline. It is hard to make exact
comparisons with other studies due to differences in
programs, perspective and whether statins had already run
out of patent (which reduces costs significantly) or not.
With regard to exploration of the subgroups, the con-
trol group CER is lower for all subgroups. Higher
educated participants and women seem to benefit most
from the investment of extra time and immediate feed-
back and motivation from self-monitoring, as the ICER
is most favourable for these two groups. Whether the
intervention programme is preferable over control treat-
ment for these groups, depends on how much a decision
maker is willing to pay for a certain decrease in SCORE
risk estimation. However, confidence intervals were very
wide and not statistically significant.
On the other hand, especially lower educated partici-
pants seemed to be better off in the control group. A
probable explanation is that for some lower educated
individuals the instructions and feedback of the self-
monitoring might have been too complex and might
have had a discouraging effect. Higher social economic
status is inversely related to cardiovascular risk [22-27].
Some investigators suggest that screening and treating high
risk individual patients might augment socio-economic
health differences, compared with whole-population ap-
proaches [28]. Self-monitoring probably enhances thesedifferences. Individuals from a higher socio-economic back-
ground who are motivated for using self-monitoring might
be asked to pay a contribution. During the SPRING-RCT,
participants were offered self-monitoring free of charge, but
self-monitoring devices are usually not reimbursed by
health insurance companies in the Netherlands.
With respect to sex, the awareness of both the public
and physicians is poor about the fact that -despite
women having lower 10-year risk estimations compared
with men- the annual death rate for CVDs is higher
among females compared with males, due to a higher
case fatality rate from coronary attacks [1,29]. Reduction
of risk factors is also effective for cardiovascular risk in
women [30]. Our study indicates that self-monitoring may
improve cardiovascular risk management in women.
There is controversy about cardiovascular risk man-
agement for specific age groups [4,6]. Both these studies
estimated long term effects and our study only evaluates
effects after one year. For this study, the intervention group
CER is higher for participants aged 65 years and older,
compared with younger participants, despite the fact that
productivity losses will be present mostly in younger par-
ticipants. Incremental cost-effectiveness ratio is more
favourable for participants aged 65 years and older.
Strengths and limitations
Strengths of this study are the pragmatic protocol and
the societal perspective. No information from the
SPRING study was available on long term effects >1 year
nor on adverse effects. No modelling was performed to
estimate for example quality adjusted life years, which
makes comparisons with some other studies difficult.
On the other hand the lack of assumptions necessary for
modelling makes the results more plain to interpret. The
group size was too limited to allow reliable cost effect-
iveness analyses in subgroups, so conclusions about sub-
groups should be considered as preliminary.
Conclusion
In the studied population, standard cardiovascular risk
management by practice nurses is more cost effective
than additional intensive counselling based on self-
monitoring. As a considerable proportion of the target
population for cardiovascular risk management will con-
sist of working individuals, productivity losses during
practice visits have to be taken into account when decid-
ing about cardiovascular risk management strategies.
The majority of costs resulted from societal costs. The
costs for cardiovascular risk management however are
found to be relatively low, for protocols based on the
Dutch General Practitioner’s Guideline on Cardiovascular
Risk Management (version 2006) [17]. Our findings sup-
port the use of this guideline for the targeted individuals
in general practice. Costs from the perspective of the
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http://www.biomedcentral.com/1471-2458/13/148patient or the general practices are even considerably
lower. A self-monitoring approach may be of interest for
subgroups like females, facing a higher case fatality ratio.
However, effects on subgroups should be further in-
vestigated, together with investigations on long term
effects.
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